[ad_1]
This “Microbiome-Targeted Therapy in Immunology-Special Study” Report has been added to ResearchAndMarkets.com provide.
The microbiome is considered to be the genetic material of all microorganisms present in and on the human body. There are a large number of resident microbial communities in the gastrointestinal (GI) tract, skin, and respiratory tract. Imbalance or damage to these populations can lead to immune disorders. Emerging therapies and increased knowledge of the microbiome are expected to help meet the unmet needs of patients with various indications in immunology. Therapies that target the microbiome are called Living Biotherapeutics (LBP) by regulatory agencies, and each of them aims to address the disease by changing the microbiome.
Currently, the United States and 5EU (France, Germany, Italy, Spain, and the United Kingdom) are developing 23 types of microbiome targeted therapies for gastrointestinal, skin diseases and respiratory diseases. Most of these drugs target gastrointestinal indications and are in the early stages of clinical development. Four pipeline drugs are in late phase II trials: 4D Pharma’s Blautix for irritable bowel syndrome, AOBiome’s B-244 for acne vulgaris and atopic dermatitis, Evero Biosciences’ EDP-1815 for psoriasis and Seres Therapeutics’ SER -287 to treat ulcerative colitis. These drugs are expected to be launched in the next five to six years.
Companies mentioned
-
4D Pharmaceutical
-
Gut Biosciences
-
Takeda Pharmaceutical
-
Seres therapy
-
Rui Biological
-
Intralox
-
Ferring International
-
Vedanta Biosciences
-
Biochemical X
-
Johnson & Johnson
-
Nubjorta
-
Branch Biology Laboratory
-
Kaleidoscope Bioscience
-
AO Biome
-
MatriSys Biological Sciences
-
Theota Therapy
-
Powerful biological sciences
-
Naked biome
-
Evelo Biosciences Corporation
Key question to answer
-
Which early and late microbiome targeted pipeline therapies for immunological indications are in clinical development?
-
What are the unmet needs currently…
The full story on Benzinga.com
[ad_2]
Source link
